Lead sponsor
Neurim Pharmaceuticals Ltd.
3 Alzheimer’s disease and related dementias trials led. Source: ClinicalTrials.gov, as of July 21, 2026.
3
Trials led
1
Ongoing
669
Total enrollment
96
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 2
2
Phase 2/3
1
Trials by status
Active, not recruiting
1
Completed
2
Trials led
TrialEligibility highlightPhaseStatusEnrollment
Safety and Efficacy of Piromelatine in Mild Alzheimer's Disease Patients (ReCOGNITION)Alzheimer's diseasePh 2Completed371
Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's DiseaseAlzheimer's diseasePh 2/3Active, not recruiting225